BeyondSpring (NASDAQ:BYSI) Stock Price Up 0.1% – Here’s Why

Posted by Stacy Sanders on Apr 24th, 2026

BeyondSpring Inc. (NASDAQ:BYSI – Get Free Report) rose 0.1% during trading on Friday . The stock traded as high as $1.7050 and last traded at $1.6620. Approximately 2,994 shares changed hands during trading, a decline of 72% from the average daily volume of 10,534 shares. The stock had previously closed at $1.66.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of BeyondSpring in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

View Our Latest Research Report on BeyondSpring

BeyondSpring Stock Up 0.1%

The stock has a market capitalization of $68.34 million, a P/E ratio of -11.08 and a beta of 0.51. The firm’s 50 day simple moving average is $1.58 and its two-hundred day simple moving average is $1.73.

BeyondSpring (NASDAQ:BYSI – Get Free Report) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.49.

Hedge Funds Weigh In On BeyondSpring

An institutional investor recently bought a new position in BeyondSpring stock. State Street Corp bought a new position in shares of BeyondSpring Inc. (NASDAQ:BYSI – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned 0.57% of BeyondSpring as of its most recent SEC filing. 40.29% of the stock is currently owned by hedge funds and other institutional investors.

BeyondSpring Company Profile

(Get Free Report)

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.